Bailey N. Scoggins

We find inhibition of survivin using YM155 to be more potent (lower-dose requirements) than the traditional, platinum-based chemo-therapy carboplatin with the same maximal efficacy (loss of cell-viability) when treating small cell lung cancer cells in vitro.